S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
NASDAQ:QURE

uniQure - QURE Stock Forecast, Price & News

$26.03
-0.26 (-0.99%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$25.39
$26.71
50-Day Range
$16.98
$27.32
52-Week Range
$12.52
$30.41
Volume
1.47 million shs
Average Volume
823,541 shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.71

uniQure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
87.1% Upside
$48.71 Price Target
Short Interest
Healthy
6.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of uniQure in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$200,363 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.57) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

470th out of 1,034 stocks

Pharmaceutical Preparations Industry

211th out of 502 stocks

QURE stock logo

About uniQure (NASDAQ:QURE) Stock

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Stock News Headlines

uniQure (NASDAQ:QURE) Shares Up 3.4%
Q2 2023 EPS Estimates for uniQure Raised by Analyst (NASDAQ:QURE)
uniQure (NASDAQ:QURE) PT Raised to $65.00 at Truist Financial
Amazon has a unique inflation problem - Reuters
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Company Calendar

Last Earnings
10/24/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QURE
Employees
463
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.71
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+87.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$329.59 million
Net Margins
-204.12%
Pretax Margin
-206.73%

Debt

Sales & Book Value

Annual Sales
$524 million
Cash Flow
$7.21 per share
Book Value
$9.00 per share

Miscellaneous

Free Float
45,364,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
1.06

Key Executives

  • Mr. Matthew Craig KapustaMr. Matthew Craig Kapusta (Age 50)
    CEO & Exec. Director
    Comp: $969.95k
  • Mr. Christian KlemtMr. Christian Klemt (Age 49)
    CFO, Principal Financial Officer & GM of Amsterdam Site
    Comp: $505.02k
  • Mr. Pierre Caloz
    Chief Operating Officer
  • Dr. Alexander E. Kuta Ph.D. (Age 62)
    Exec. VP of Quality & Regulatory Affairs
    Comp: $649.26k
  • Dr. Ricardo Dolmetsch Ph.D.Dr. Ricardo Dolmetsch Ph.D. (Age 53)
    Pres of R&D
    Comp: $795.35k
  • Prof. Hugo Katus
    Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Mr. David Cerveny (Age 55)
    Chief Legal Officer, Gen. Counsel & Sec.
  • Dr. Tamara Tugal Ph.D.
    MBA, Bus. Devel. Director
  • Ms. Erin Boyer
    Chief People & Culture Office
  • Ms. Maria E. Cantor (Age 54)
    Chief Corp. Affairs Officer













QURE Stock - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price forecast for 2023?

7 brokers have issued 1 year price targets for uniQure's shares. Their QURE share price forecasts range from $24.00 to $65.00. On average, they expect the company's share price to reach $48.71 in the next twelve months. This suggests a possible upside of 87.1% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2022?

uniQure's stock was trading at $20.74 on January 1st, 2022. Since then, QURE stock has increased by 25.5% and is now trading at $26.03.
View the best growth stocks for 2022 here
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its quarterly earnings data on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.26. The biotechnology company had revenue of $2 million for the quarter, compared to analyst estimates of $2.13 million. uniQure had a negative net margin of 204.12% and a negative trailing twelve-month return on equity of 24.47%. The company's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.21) EPS.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.46%), Point72 Asset Management L.P. (9.10%), State Street Corp (6.54%), PFM Health Sciences LP (5.11%), Vanguard Group Inc. (3.06%) and 683 Capital Management LLC (2.93%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Pierre Caloz, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends
.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $26.03.

How much money does uniQure make?

uniQure (NASDAQ:QURE) has a market capitalization of $1.22 billion and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or ($2.69) on an earnings per share basis.

How many employees does uniQure have?

The company employs 463 workers across the globe.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.

This page (NASDAQ:QURE) was last updated on 12/4/2022 by MarketBeat.com Staff